Ofra Novoplansky

Ofra Novoplansky

Auto-generated profile, based on publicly available information

Ofra Novoplansky

The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ECEmiliano Cocco
Emiliano Cocco
JLJi Eun Lee
Ji Eun Lee
SKSrinivasaraghavan Kannan
Srinivasaraghavan Kannan
ASAlison M. Schram
Alison M. Schram
HWHelen H. Won
Helen H. Won
MSMaurizio Scaltriti
Maurizio Scaltriti
On-target resistance to next-generation TRK inhibitors in TRK fusion–positive cancers is largely uncharacterized. In patients with these tumors, we found that TRK xDFG mutations confer resistance to type I next-generation TRK inhibitors designed to maintain potency against several kinase domain mutations. Computational modeling and biochemical assays showed that TRKAG667 and TRKCG696 xDFG substitutions reduce drug binding by generating steric hindrance. Concurrently, these mutations stabilize the inactive (DFG-out) conformations of the kinases, thus sensitizing these kinases to type II TRK inhibitors. Consistently, type II inhibitors impede the growth and TRK-mediated signaling of xDFG-mutant isogenic and patient-derived models. Collectively, these data demonstrate that adaptive conformational resistance can be abrogated by shifting kinase engagement modes. Given the prior identification of paralogous xDFG resistance mutations in other oncogene-addicted cancers, these findings provide insights into rational type II drug design by leveraging inhibitor class affinity switching to address recalcitrant resistant alterations. Significance: In TRK fusion–positive cancers, TRK xDFG substitutions represent a shared liability for type I TRK inhibitors. In contrast, they represent a potential biomarker of type II TRK inhibitor activity. As all currently available type II agents are multikinase inhibitors, rational drug design should focus on selective type II inhibitor creation. This article is highlighted in the In This Issue feature, p. 1

3 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
KYKsenia M Yegodayev
Ksenia M Yegodayev
ONOfra Novoplansky
Ofra Novoplansky
AGArtemiy Golden
Artemiy Golden
MPManu Prasad
Manu Prasad
LLLiron Levin
Liron Levin
MEMoshe Elkabets
Moshe Elkabets
Most head and neck cancer (HNC) patients are resistant to cetuximab, an antibody against the epidermal growth factor receptor. Such therapy resistance is known to be mediated, in part, by stromal cells surrounding the tumor cells; however, the mechanisms underlying such a resistance phenotype remain unclear. To identify the mechanisms of cetuximab resistance in an unbiased manner, RNA-sequencing (RNA-seq) of HNC patient-derived xenografts (PDXs) was performed. Comparing the gene expression of HNC-PDXs before and after treatment with cetuximab indicated that the transforming growth factor-beta (TGF-beta) signaling pathway was upregulated in the stromal cells of PDXs that progressed on cetuximab treatment (CetuximabProg-PDX). However, in PDXs that were extremely sensitive to cetuximab (CetuximabSen-PDX), the TGF-beta pathway was downregulated in the stromal compartment. Histopathological analysis of PDXs showed that TGF-beta-activation was detected in cancer-associated fibroblasts (CAFs) of CetuximabProg-PDX. These TGF-beta-activated CAFs were sufficient to limit cetuximab efficacy in vitro and in vivo. Moreover, blocking the TGF-beta pathway using the SMAD3 inhibitor, SIS3, enhanced cetuximab efficacy and prevented the progression of CetuximabProg-PDX. Altogether, our findings indicate that TGF-beta-activated CAFs play a role in limiting cetuximab efficacy in HNC.

1 February 2021 in Cancer Letters
Verified
Journal Article
Closed access
EAElham Alsahafi
Elham Alsahafi
STSelvam Thavaraj
Selvam Thavaraj
NSNazanin Sarvestani
Nazanin Sarvestani
ONOfra Novoplansky
Ofra Novoplansky
MEMoshe Elkabets
Moshe Elkabets
MLMain Figures Legends
Main Figures Legends

6 May 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
ONOfra Novoplansky
Ofra Novoplansky
SJSankar Jagadeeshan
Sankar Jagadeeshan
OROhad Regev
Ohad Regev
IMIdan Menashe
Idan Menashe
MEMoshe Elkabets
Moshe Elkabets
In light of the development of RAS inhibitors, a reliable assessment of the prevalence of RAS mutations and their correlation with the clinical features of patients with HNC is crucially needed. This meta-analysis compiles the findings of 149 studies with over 8500 HNC patients and assesses the global prevalence of mutations in the HRAS, KRAS and NRAS genes. The available data were stratified according to geographical region, clinical features, and tumor characteristics, including human papillomavirus (HPV) infection status and tumor stage. In addition, the distribution of codon substitutions in each RAS gene was assessed. The estimated mutation rate is highest for HRAS (7%), followed by KRAS (2.89%) and NRAS (2.20%). HRAS prevalence in South Asia (15.28%) is twice as high as the global estimate. HRAS mutations are more prevalent in oral cavity and salivary gland tumors. In contrast, KRAS mutations are found more frequently in sinonasal tumors, and NRAS mutations are found chiefly in tumors of the nasopharynx. OR analyses show a significant association between HRAS mutations and a high tumor stage (OR=3.63). In addition, there is a significant association between HPV-positive status and KRAS mutations (OR=2.09). This study highlights RAS as a potential therapeutic target in certain subsets of HNC patients.


3 April 2023
Verified
Other
Open access
ECEmiliano Cocco
Emiliano Cocco
JLJi Eun Lee
Ji Eun Lee
SKSrinivasaraghavan Kannan
Srinivasaraghavan Kannan
ASAlison M. Schram
Alison M. Schram
HWHelen H. Won
Helen H. Won
MSMaurizio Scaltriti
Maurizio Scaltriti